Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Mersana gets its rescue bid
But the Day One deal is still 29% below where the shares stood at the start of this year.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Crispr cans a next-gen project
The CD70-targeting CTX131 heads for the scrapheap.
Lyell shuffles the pipeline again
After more discontinuations, a new deal brings in fresh blood.
SITC 2025 – fresh hope for Summit's Harmoni
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
An ozekibart reminder about liver toxicity
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
